☆ 4.3 Article

Tumoral Ki67 and PSMA Expression in Fresh Pre-PSMA-RLT Biopsies and Its Relation With PSMA-PET Imaging and Outcomes of PSMA-RLT in Patients With mCRPC

CLINICAL GENITOURINARY CANCER (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Radiology, Nuclear Medicine & Medical Imaging

[68Ga]Ga-PSMA-11 PET imaging as a predictor for absorbed doses in organs at risk and small lesions in [177Lu]Lu-PSMA-617 treatment

Steffie M. B. Peters et al.

Summary: Predicting absorbed doses based on [Ga-68]Ga-PSMA-PET/CT scans can improve patient selection and individualize treatment in [Lu-177]Lu-PSMA therapy. Results show that PET scans can be used to predict absorbed doses to organs and lesions, aiding in treatment management and potentially increasing therapy personalization.

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2022)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

Intra-therapeutic dosimetry of [177Lu]Lu-PSMA-617 in low-volume hormone-sensitive metastatic prostate cancer patients and correlation with treatment outcome

Steffie M. B. Peters et al.

Summary: This study found that the kinetics of [Lu-177]Lu-PSMA therapy in mHSPC patients are similar to those in mCRPC patients, indicating less concern for tumor sink effect. The absorbed dose in lesions was high and correlated with treatment response.

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2022)

添加到收藏夹

Article Oncology

Impact of DNA damage repair defects on response to PSMA radioligand therapy in metastatic castration-resistant prostate cancer

Bastiaan M. Prive et al.

Summary: This study found that in mCRPC patients undergoing DDR gene testing and receiving PSMA-RLT treatment, tumors with DDR abnormalities do not necessarily show better treatment responses.

PROSTATE CANCER AND PROSTATIC DISEASES (2022)

添加到收藏夹

Review Urology & Nephrology

EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. Part II-2020 Update: Treatment of Relapsing and Metastatic Prostate Cancer

Philip Cornford et al.

Summary: The 2020 EAU-EANM-ESTRO-ESUR-SIOG guidelines provide evidence-based guidance on the treatment of relapsing, metastatic, and castration-resistant prostate cancer. These guidelines are continuously updated to reflect the latest research findings in the field.

EUROPEAN UROLOGY (2021)

添加到收藏夹

Review Urology & Nephrology

Genomic and phenotypic heterogeneity in prostate cancer

Michael C. Haffner et al.

Summary: Prostate cancer is heterogeneous, with primary tumors being multifocal and metastatic tumors potentially originating from a single clone but exhibiting subclonal heterogeneity at the genomic, epigenetic, and phenotypic levels. The complex heterogeneous constellation of molecular alterations poses challenges for diagnosis and treatment of prostate cancer.

NATURE REVIEWS UROLOGY (2021)

添加到收藏夹

Article Oncology

Clinical-Prostate cancer Clinical outcomes and molecular profiling of advanced metastatic castration-resistant prostate cancer patients treated with 225Ac-PSMA-617 targeted alpha-radiation therapy

Maarten J. van der Doelen et al.

Summary: The study evaluated the efficacy of Ac-225-PSMA TAT in advanced mCRPC patients and its impact on QoL. The results showed remarkable survival and biochemical responses, with clinically relevant QoL improvement observed in patients. However, xerostomia was found to be nontransient. Baseline immunohistochemical PSMA expression and DNA damage repair status may serve as potential predictive biomarkers for response to Ac-225-PSMA TAT.

UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2021)

添加到收藏夹

Article Oncology

Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

Hyuna Sung et al.

Summary: The global cancer burden in 2020 saw an estimated 19.3 million new cancer cases and almost 10.0 million cancer deaths. Female breast cancer surpassed lung cancer as the most commonly diagnosed cancer, while lung cancer remained the leading cause of cancer death. These trends are expected to rise in 2040, with transitioning countries experiencing a larger increase compared to transitioned countries due to demographic changes and risk factors associated with globalization and a growing economy. Efforts to improve cancer prevention measures and provision of cancer care in transitioning countries will be crucial for global cancer control.

CA-A CANCER JOURNAL FOR CLINICIANS (2021)

添加到收藏夹

Review Radiology, Nuclear Medicine & Medical Imaging

Factors predicting biochemical response and survival benefits following radioligand therapy with [177Lu]Lu-PSMA in metastatic castrate-resistant prostate cancer: a review

Reyhaneh Manafi-Farid et al.

Summary: Multiple factors have been evaluated for predicting response to [Lu-177]Lu-PSMA RLT, with diverse and sometimes divergent results. However, reduction in PSA levels after treatment has consistently been shown to predict prolonged survival. Further prospective randomized trials are needed to determine independent prognostic factors and clarify the clinical and survival benefits of [Lu-177]Lu-PSMA RLT.

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2021)

添加到收藏夹

Article Medicine, General & Internal

[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial

Michael S. Hofman et al.

Summary: [Lu-177]Lu-PSMA-617 showed a higher PSA response and fewer grade 3-4 adverse events compared to cabazitaxel in men with metastatic castration-resistant prostate cancer.

LANCET (2021)

添加到收藏夹

Article Oncology

Lutetium-177-PSMA-617 in Low-Volume Hormone-Sensitive Metastatic Prostate Cancer: A Prospective Pilot Study

Bastiaan M. Prive et al.

Summary: In this prospective study, Lu-177-PSMA appeared to be a feasible and safe treatment modality for patients with low-volume metastatic hormone-sensitive prostate cancer, showing good treatment effect and minimal adverse events.

CLINICAL CANCER RESEARCH (2021)

添加到收藏夹

Review Radiology, Nuclear Medicine & Medical Imaging

Global experience with PSMA-based alpha therapy in prostate cancer

Mike M. Sathekge et al.

Summary: PSMA-based alpha therapy shows great potential in treating mCRPC, as it utilizes unique mechanisms of action that are difficult to achieve with other conventional therapies. A better understanding of the strengths and limitations of PAT may help in creating an effective therapy and designing a rational combinatorial approach to treatment by targeting different tumor pathways.

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2021)

添加到收藏夹

Article Oncology

Nomograms to predict outcomes after 177Lu-PSMA therapy in men with metastatic castration-resistant prostate cancer: an international, multicentre, retrospective study

Andrei Gafita et al.

Summary: Nomograms developed in this study can predict outcomes after Lu-177-PSMA in patients with mCRPC. These predictive models can assist in guiding clinical trial design and individual clinical decision-making, especially in institutions where Lu-177-PSMA is introduced as a novel therapeutic option.

LANCET ONCOLOGY (2021)

添加到收藏夹

Article Medicine, General & Internal

Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer

Oliver Sartor et al.

Summary: The radioligand therapy with Lu-177-PSMA-617 prolonged both imaging-based progression-free survival and overall survival in patients with PSMA-positive metastatic castration-resistant prostate cancer when added to standard care. Adverse events were more common with Lu-177-PSMA-617 but did not significantly impact quality of life.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

Response Prediction of 177Lu-PSMA-617 Radioligand Therapy Using Prostate-Specific Antigen, Chromogranin A, and Lactate Dehydrogenase

Hendrik Rathke et al.

JOURNAL OF NUCLEAR MEDICINE (2020)

添加到收藏夹

Review Oncology

Lutetium-177 prostate-specific membrane antigen (PSMA) theranostics: practical nuances and intricacies

Amir Iravani et al.

PROSTATE CANCER AND PROSTATIC DISEASES (2020)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

Prognostic biomarkers in men with metastatic castration-resistant prostate cancer receiving [177Lu]-PSMA-617

Justin Ferdinandus et al.

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2020)

添加到收藏夹

Article Medicine, Research & Experimental

Efficacy and safety of 225Ac-PSMA-617 targeted alpha therapy in metastatic castration-resistant Prostate Cancer patients

Madhav Prasad Yadav et al.

THERANOSTICS (2020)

添加到收藏夹

Review Oncology

The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy

Daniela Bruni et al.

NATURE REVIEWS CANCER (2020)

添加到收藏夹

Article Urology & Nephrology

Prostate-specific Membrane Antigen Heterogeneity and DNA Repair Defects in Prostate Cancer

Alec Paschalis et al.

EUROPEAN UROLOGY (2019)

添加到收藏夹

Article Urology & Nephrology

Treatment Outcome, Toxicity, and Predictive Factors for Radioligand Therapy with 177Lu-PSMA-I&T in Metastatic Castration-resistant Prostate Cancer

Matthias M. Heck et al.

EUROPEAN UROLOGY (2019)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

Therapeutic efficacy, prognostic variables and clinical outcome of 177Lu-PSMA-617 PRLT in progressive mCRPC following multiple lines of treatment: prognostic implications of high FDG uptake on dual tracer PET-CT vis-a-vis Gleason score in such cohort

Sonam Suman et al.

BRITISH JOURNAL OF RADIOLOGY (2019)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

Dosimetry of 177Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer: Correlations Between Pretherapeutic Imaging and Whole-Body Tumor Dosimetry with Treatment Outcomes

John Violet et al.

JOURNAL OF NUCLEAR MEDICINE (2019)

添加到收藏夹

Article Oncology

Poor Outcomes for Patients with Metastatic Castration-resistant Prostate Cancer with Low Prostate-specific Membrane Antigen (PSMA) Expression Deemed Ineligible for 177Lu-labelled PSMA Radioligand Therapy

Sue Ping Thang et al.

EUROPEAN UROLOGY ONCOLOGY (2019)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

Prostate Cancer Molecular Imaging Standardized Evaluation (PROMISE): Proposed miTNM Classification for the Interpretation of PSMA-Ligand PET/CT

Matthias Eiber et al.

JOURNAL OF NUCLEAR MEDICINE (2018)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

Immunohistochemical Validation of PSMA Expression Measured by Ga-68-PSMA PET/CT in Primary Prostate Cancer

Nadine Woythal et al.

JOURNAL OF NUCLEAR MEDICINE (2018)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

Investigation of receptor radionuclide therapy with Lu-177-DOTATATE in patients with GEP-NEN and a high Ki-67 proliferation index

Silvia Nicolini et al.

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2018)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

Targeted α-Therapy of Metastatic Castration-Resistant Prostate Cancer with 225Ac-PSMA-617:Swimmer-Plot Analysis Suggests Efficacy Regarding Duration of Tumor Control

Clemens Kratochwil et al.

JOURNAL OF NUCLEAR MEDICINE (2018)

添加到收藏夹

Article Oncology

[177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study

Michael S. Hofman et al.

LANCET ONCOLOGY (2018)

添加到收藏夹

Article Oncology

Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3

Howard I. Scher et al.

JOURNAL OF CLINICAL ONCOLOGY (2016)

添加到收藏夹

Article Multidisciplinary Sciences

Correlation between the Uptake of 18F-Fluorodeoxyglucose (18F-FDG) and the Expression of Proliferation-Associated Antigen Ki-67 in Cancer Patients: A Meta-Analysis

Sheng-ming Deng et al.

PLOS ONE (2015)

添加到收藏夹

Review Oncology

Ki67 is a promising molecular target in the diagnosis of cancer

Lian Tao Li et al.

MOLECULAR MEDICINE REPORTS (2015)

添加到收藏夹

Article Multidisciplinary Sciences

Prevalence of Prostate Cancer Clinical States and Mortality in the United States: Estimates Using a Dynamic Progression Model

Howard I. Scher et al.

PLOS ONE (2015)

添加到收藏夹

Article Oncology

EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study

Robert Pirker et al.

LANCET ONCOLOGY (2012)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

Impact of the Ki-67 proliferation index on response to peptide receptor radionuclide therapy

Samer Ezziddin et al.

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2011)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.